# 510(k) Premarket Notification Checklist

Complete submission checklist for FDA 510(k) premarket notifications.

**Version:** 1.0.0
**Regulation:** 21 CFR Part 807 Subpart E
**Guidance:** "The 510(k) Program: Evaluating Substantial Equivalence" (July 2014)

---

## Administrative Elements

### Cover Sheet and Forms

- [ ] **FDA Form 3514** - Cover sheet with all required information
  - Device trade/proprietary name
  - Device common/classification name
  - Establishment registration number
  - Device class (if known)
  - Action taken (initial submission, amendment, resubmission)
  - Device classification information
  - Submitter contact information

- [ ] **510(k) Summary** or **Statement of Substantial Equivalence**
  - Choose one (most submit summary for public posting)
  - If summary: must be within 6 pages and include all required elements per 21 CFR 807.92(b)
  - If statement: commitment to provide summary within 30 days of request

- [ ] **Truthful and Accuracy Statement**
  - Signed by authorized representative
  - Confirms all information is truthful and accurate

- [ ] **Class III Certification Statement** (if applicable)
  - For devices automatically classified as Class III
  - Certifies no PMA or notice of completion of PDP in effect

- [ ] **Financial Disclosure Statements** (if clinical studies included)
  - FDA Form 3454 for each covered clinical study
  - Certification of financial interests

- [ ] **User Fee Cover Sheet** (FDA Form 3601)
  - Small business qualification documentation (if claiming reduced fee)
  - Multiple 510(k) submission rider (if applicable)

### Table of Contents

- [ ] **Comprehensive Table of Contents**
  - All sections numbered
  - Page numbers for all sections
  - Clear hierarchical organization

---

## Device Description

### Device Overview

- [ ] **Device Name and Classification**
  - Trade name / proprietary name
  - Common name
  - Classification name
  - Product code (if known)
  - 21 CFR regulation number (if known)

- [ ] **Detailed Device Description**
  - Physical description (dimensions, materials, components)
  - Principles of operation
  - Labeled diagrams or photos
  - Device specifications
  - Variants or configurations (if applicable)

- [ ] **Engineering Drawings**
  - Assembly drawings
  - Component drawings
  - Dimensional specifications
  - Material specifications
  - Exploded views (if complex assembly)

- [ ] **Materials List**
  - All materials in contact with patient or user
  - Material grades and specifications
  - Biocompatibility considerations flagged
  - Patient-contacting vs non-patient-contacting materials identified

### Intended Use

- [ ] **Intended Use Statement**
  - General purpose of the device
  - Device function clearly described
  - Target patient population

- [ ] **Indications for Use Form** (FDA Form 3881)
  - Specific disease or condition addressed
  - Prescription vs OTC designation
  - Target anatomical site
  - Patient population (age, condition, severity)
  - Contraindications (if any)
  - Signed and dated by authorized representative

### Comparison to Predicate

- [ ] **Predicate Device Identification**
  - Predicate device name and manufacturer
  - 510(k) number (K######) of predicate clearance
  - Predicate product code
  - Reference to FDA 510(k) database

- [ ] **Device Comparison Table**
  - Side-by-side comparison of subject device vs predicate
  - Intended use comparison
  - Technology characteristics comparison
  - Materials comparison
  - Performance specifications comparison
  - Design specifications comparison

- [ ] **Substantial Equivalence Discussion**
  - Same intended use justification
  - Same technological characteristics OR
  - Different technological characteristics with justification that:
    - They do not raise different questions of safety/effectiveness
    - Device is as safe and effective as predicate
  - Performance data supporting equivalence

---

## Performance Data

### Bench Testing

- [ ] **Test Protocols**
  - Detailed test methods
  - Acceptance criteria
  - Sample sizes and statistical justification

- [ ] **Test Results**
  - Complete test data
  - Statistical analysis (if applicable)
  - Comparison to predicate performance (if available)
  - Comparison to relevant standards

- [ ] **Performance Standards Compliance**
  - FDA-recognized consensus standards used
  - Test reports from accredited laboratories
  - Certificates of conformance
  - Common standards:
    - Electrical safety (IEC 60601 series)
    - EMC (IEC 60601-1-2)
    - Biocompatibility (ISO 10993)
    - Sterilization validation (ISO 11135, 11137)
    - Packaging validation (ASTM standards)

### Biocompatibility

- [ ] **Biocompatibility Assessment**
  - Risk assessment per ISO 10993-1
  - Patient contact categorization (surface, external communicating, implant)
  - Contact duration (limited, prolonged, permanent)

- [ ] **Biocompatibility Testing** (as applicable based on risk assessment)
  - Cytotoxicity (ISO 10993-5)
  - Sensitization (ISO 10993-10)
  - Irritation/intracutaneous reactivity (ISO 10993-10)
  - Systemic toxicity (ISO 10993-11)
  - Subchronic/chronic toxicity (ISO 10993-11)
  - Genotoxicity (ISO 10993-3)
  - Implantation (ISO 10993-6)
  - Hemocompatibility (ISO 10993-4)
  - Chemical characterization (ISO 10993-18)
  - Material equivalence justification if using existing data

### Sterilization (if applicable)

- [ ] **Sterilization Method Documentation**
  - Method description (EtO, radiation, steam, etc.)
  - Validation per relevant standard:
    - EtO: ISO 11135
    - Radiation: ISO 11137
    - Steam: ISO 17665

- [ ] **Sterilization Validation**
  - Installation qualification (IQ)
  - Operational qualification (OQ)
  - Performance qualification (PQ)
  - Routine monitoring procedures
  - Revalidation schedule

- [ ] **Sterility Assurance Level (SAL)**
  - SAL 10^-6 for most devices
  - Sterility test results (ISO 11737)
  - Endotoxin testing if applicable (USP <85>, <161>)

### Shelf Life and Stability

- [ ] **Shelf Life Determination**
  - Real-time aging study (preferred) or
  - Accelerated aging study (with justification)
  - Aging protocol per ASTM F1980

- [ ] **Package Integrity Testing**
  - Package validation per ASTM standards
  - Seal strength testing
  - Package integrity testing (dye penetration, bubble test)
  - Transport simulation testing

### Software (if applicable)

- [ ] **Level of Concern Determination**
  - Minor, Moderate, or Major
  - Justification for level assigned

- [ ] **Software Documentation** (level dependent)
  - Software description
  - Device hazard analysis
  - Software requirements specification (SRS)
  - Architecture design chart
  - Software development environment description
  - Verification and validation documentation
  - Revision level history
  - Unresolved anomalies list
  - Cybersecurity documentation (if networked/wirelessly enabled)

- [ ] **Software Standards Compliance**
  - IEC 62304:2006 (Medical device software lifecycle)
  - IEC 62366:2015 (Usability engineering)
  - Cybersecurity guidance compliance (if applicable)

### Electromagnetic Compatibility (EMC) / Electrical Safety

- [ ] **EMC Testing** (for devices with electronics)
  - IEC 60601-1-2 testing
  - Emissions testing
  - Immunity testing
  - Test reports from accredited lab

- [ ] **Electrical Safety Testing**
  - IEC 60601-1 compliance
  - Protective earth resistance
  - Leakage current testing
  - Test reports from accredited lab

---

## Clinical Data (if required)

### Clinical Study

- [ ] **IRB Approval**
  - IRB approval letter
  - Study protocol approved by IRB
  - Informed consent form approved by IRB

- [ ] **Clinical Study Protocol**
  - Objectives and endpoints (primary, secondary)
  - Study design (randomized, blinded, controlled, etc.)
  - Inclusion/exclusion criteria
  - Sample size justification
  - Statistical analysis plan
  - Data monitoring procedures
  - Adverse event reporting procedures

- [ ] **Clinical Study Report**
  - Patient demographics
  - Study conduct and timeline
  - Data analysis and results
  - Safety data (adverse events, device deficiencies)
  - Effectiveness data
  - Statistical analysis results
  - Discussion and conclusions

- [ ] **IDE Information** (if study conducted under IDE)
  - IDE number (if applicable)
  - Confirmation of IDE compliance
  - Any FDA communications regarding the IDE

### Clinical Literature (if used in lieu of study)

- [ ] **Literature Search Strategy**
  - Databases searched
  - Search terms used
  - Date range
  - Inclusion/exclusion criteria

- [ ] **Literature Summary Table**
  - Study design, endpoints, patient population
  - Results relevant to substantial equivalence

- [ ] **Full Text Articles**
  - All cited literature provided as appendix

---

## Labeling

### Draft Labeling

- [ ] **Labels** (all labels that will appear on device, packaging)
  - Device label
  - Outer packaging label
  - Unit carton label
  - All language variations if multilingual

- [ ] **Instructions for Use (IFU)**
  - Device description
  - Intended use and indications
  - Contraindications
  - Warnings and precautions
  - Operating instructions
  - Cleaning/reprocessing instructions (if reusable)
  - Storage and handling
  - Troubleshooting
  - Symbols glossary
  - Technical specifications
  - Manufacturer information

- [ ] **Patient Labeling** (if applicable)
  - Patient information leaflet
  - Home use instructions
  - Safety information for patients

- [ ] **Marketing Materials** (if submitting for review)
  - Brochures
  - Website content
  - Promotional materials

### Labeling Standards Compliance

- [ ] **UDI Labeling**
  - UDI-DI on label
  - UDI compliance strategy
  - GUDID submission plan

- [ ] **Symbols Compliance**
  - ISO 15223-1 symbols (if used)
  - Symbol glossary in IFU

---

## Manufacturing Information

### Manufacturing Overview

- [ ] **Manufacturing Site(s)**
  - Name and address of all manufacturing sites
  - Establishment registration number(s)
  - Site functions (manufacturing, sterilization, packaging, etc.)
  - Contract manufacturers identified

- [ ] **Manufacturing Process**
  - Process flow diagram
  - Key process steps described
  - Critical process parameters identified
  - In-process controls

- [ ] **Quality System Information**
  - QSR compliance statement (21 CFR Part 820)
  - ISO 13485 certification (if applicable)
  - ISO 13485 certificate provided

---

## Risk Analysis

- [ ] **Risk Management File**
  - Risk management plan
  - Hazard analysis
  - Risk evaluation and control measures
  - Residual risk assessment
  - Risk management report
  - Compliance with ISO 14971:2019

- [ ] **Hazards Identified and Mitigated**
  - Biological hazards
  - Chemical hazards
  - Electrical hazards
  - Mechanical hazards
  - Software hazards (if applicable)
  - Usability hazards
  - Environmental hazards

---

## Additional Sections (as applicable)

### Reprocessing/Reuse

- [ ] **Cleaning and Disinfection Instructions**
  - Validated cleaning protocol
  - Validated disinfection/sterilization protocol (if reusable)
  - Reprocessing validation data

- [ ] **Reuse Limitations**
  - Maximum reuse cycles
  - Inspection criteria between uses
  - End-of-life criteria

### Combination Products

- [ ] **Combination Product Statement**
  - Primary mode of action determination
  - Jurisdiction (device-led, drug-led, biologic-led)
  - RFD (Request for Designation) if submitted

- [ ] **Constituent Part Information**
  - Drug/biologic component details (if applicable)
  - Cross-reference to drug master file (if applicable)

### Accessories

- [ ] **Accessory Information**
  - All accessories listed
  - Essential vs. non-essential accessories
  - Compatibility testing with accessories

---

## Pre-Submission Checklist

Before submitting, verify:

- [ ] **Completeness Review**
  - All sections address FDA's questions
  - No placeholders or "to be determined"
  - All cross-references accurate
  - All appendices included and referenced

- [ ] **Internal Review**
  - Regulatory review completed
  - Technical review completed
  - Quality review completed
  - Executive sign-off obtained

- [ ] **Formatting and Organization**
  - Professional formatting
  - Consistent fonts and styles
  - Clear section numbering
  - Page numbers on all pages
  - Comprehensive bookmarks in PDF
  - File size optimized for submission

- [ ] **Submission Package**
  - Cover letter prepared
  - eSubmitter account set up
  - User fees paid or small business certification ready
  - Backup copy of entire submission maintained

---

## Common Deficiencies to Avoid

**Predicate Selection:**
- ❌ Using invalidated or withdrawn predicate
- ❌ Predicate subject to PMA or special controls
- ❌ Insufficient predicate comparison

**Performance Data:**
- ❌ Incomplete test data or protocols
- ❌ Testing not to FDA-recognized standards
- ❌ Inadequate sample sizes without justification
- ❌ Missing acceptance criteria

**Software:**
- ❌ Level of concern not justified
- ❌ Insufficient software documentation for level of concern
- ❌ Missing cybersecurity information for networked devices

**Biocompatibility:**
- ❌ Missing risk assessment per ISO 10993-1
- ❌ Testing not appropriate for contact type/duration
- ❌ Material equivalence claims not adequately supported

**Labeling:**
- ❌ Indications for use don't match testing
- ❌ Contraindications or warnings missing
- ❌ IFU incomplete or unclear

**Clinical Data (when required):**
- ❌ Inadequate sample size
- ❌ Endpoints not appropriate for intended use
- ❌ Statistical analysis flawed or missing

---

## Estimated Timeline

**Preparation Phase:** 2-6 months
- Design verification and validation testing
- Documentation compilation
- Internal reviews

**Submission Phase:** 1-2 weeks
- Final review and assembly
- eSTAR upload
- User fee payment

**FDA Review:** 3-6 months (goal: 90 days)
- Initial review: 0-30 days (refuse to accept decision)
- Substantive review: 30-90 days
- Additional information requests may extend timeline
- Average: 3-6 months from submission to clearance

**Total: 5-14 months** from start of preparation to FDA clearance

---

## Resources

**FDA Guidance:**
- "The 510(k) Program: Evaluating Substantial Equivalence" (July 2014)
- "Format for Traditional and Abbreviated 510(k)s" (September 2019)
- "Refuse to Accept Policy for 510(k)s" (June 2019)
- Device-specific guidance documents as applicable

**FDA Databases:**
- 510(k) Premarket Notification Database: Search predicates and review clearance letters
- Product Classification Database: Find product code and regulation
- FDA-Recognized Consensus Standards Database: Identify applicable standards

**Submission:**
- eSTAR (Electronic Submission Template and Resource): https://www.fda.gov/estar
- User Fee Information: https://www.fda.gov/medical-devices/premarket-submissions/user-fees

---

**Last Updated:** 2024-11-16
**Version:** 1.0.0

**Note:** This checklist is a guide. Specific devices may require additional information. Consult device-specific guidance documents and consider a Pre-Submission meeting with FDA for novel devices or unclear requirements.
